Candriam SCA’s ARK Genomic Revolution ETF ARKG Stock Holding History

Candriam SCA’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,740	Closed	-$808K	–	878
2021 Q2	$808K	Buy	8,740 +1,240	+17%	+$105K	0.01%	749
2021 Q1	$668K	Hold	7,500	–	–	0.01%	688
2020 Q4	$696K	Buy	7,500 +3,500	+88%	+$279K	0.01%	700
2020 Q3	$255K	Buy	+4,000	New	+$234K	﹤0.01%	745

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Candriam SCA's ARKG Position: Q3 2021 in Review

Candriam SCA sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2021, closing a stake of 8,740 shares — an estimated $808K sold.

Candriam SCA first reported a position in ARKG in Q3 2020 and held it in 4 quarters. The position peaked at $808K in Q2 2021. 468 funds tracked by Wall St. Rank hold ARKG as of Q3 2021.

Candriam SCA reported no remaining ARK Genomic Revolution ETF position as of Q3 2021 after selling out during the quarter.
Candriam SCA sold 8,740 ARK Genomic Revolution ETF shares in Q3 2021, an estimated $808K.
Candriam SCA first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 4 quarters.
Candriam SCA's ARK Genomic Revolution ETF position peaked at $808K in Q2 2021.
468 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2021.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.